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a  b  s  t  r  a  c  t
Female patient, complaining of weakness and pain in hypogastric, was admitted to the
emergency department of the University Hospital of the West of Paraná (HUOP). During the
interview reported treatment of chronic infection with hepatitis C virus (HCV) with pegin-
terferon and ribavirin. Among the laboratory tests ordered, the search for self-antibodies
against cellular antigens, traditionally known as antinuclear factor, showed ﬂuorescence
shaped like rods and/or rings in the cytoplasm of cells. This study attempts to clarify the
relationship between this pattern not yet completely understood and the clinical picture of
the  patient. This pattern is characterized by 3–10 m rods or rings with 2–5 m in diame-
ter  scattered throughout the cytoplasm of the cell. Therefore, this new standard has been
designated as “rods and rings” (RR). The antigenic target of this reaction was identiﬁed as
inosine-5′-monophosphate dehydrogenase type 2 (IMPDH2) which is a key enzyme in the
synthesis of purine nucleotides. The IMPDH2 enzyme aggregated or modiﬁed shaped RR
in  those patients treated with ribavirin may become antigenic and induce an autoimmune
response. It is possible that interferon alpha stimulates the occurrence of anti-RR reactivity
apparently induced by ribavirin. So far it is not known why the standard RR in HEp2 cells
occurs  only in a fraction of patients with HCV. Previous studies presented in this paper allow
afﬁrming that these antibodies associated with the standard RR are strongly related to hep-
atitis  C. Moreover, it can be stated that the occurrence of anti-RR reactivity is promoted bycombination therapy with interferon and ribavirin.
© 2014 Elsevier Editora Ltda. All rights reserved.
 Study conducted at Diagnostic and Therapeutic Support Service (SADT), Hospital Universitário do Oeste do Paraná (HUOP-Unioeste).
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Induc¸ão do  padrão  citoplasmático  em  forma  de  “bastões  e  anéis”  através
do  tratamento  da  hepatite  C:  relato  de  caso
Palavras-chave:
Hepatite C
Autoanticorpos
Bastões e anéis
Padrão citoplasmático
r  e  s  u  m  o
Paciente do sexo feminino, queixando-se de astenia e dor em hipogastro, foi admitida
no  pronto-socorro do Hospital Universitário do Oeste do Paraná (HUOP). Durante a anam-
nese  relatou tratamento de infecc¸ão crônica pelo vírus da hepatite C (VHC) com inteferon
peguilado e ribavirina. Dentre os exames laboratoriais solicitados, a pesquisa de autoan-
ticorpos contra antígenos celulares (PAAC-HEp-2), conhecido tradicionalmente como fator
antinúcleo (FAN), apresentou ﬂuorescência em forma de bastões e/ou anéis no citoplasma
das células. Esse padrão é caracterizado por bastões de 3-10 m e anéis com 2-5 m de
diâmetro espalhados através do citoplasma da célula. Portanto, esse novo padrão tem sido
designado como “bastões e anéis” (traduzido do inglês: Rods and Rings, RR). O alvo antigênico
dessa reac¸ão foi identiﬁcado como inosina-5′-monofosfato desidrogenase tipo 2 (IMPDH2)
que  é uma enzima chave na síntese de nucleotídeos púricos. A enzima IMPDH2 agregada ou
modiﬁcada em forma de RR nos pacientes tratados com ribavirina pode tornar-se antigênica
e  induzir uma resposta autoimune. É possível que o interferon alfa estimule a ocorrência de
reatividade anti-RR aparentemente induzida pela ribavirina. Até o momento não se sabe por
que  o padrão RR em células HEp-2 ocorrem apenas em uma frac¸ão de pacientes portadores
do VHC. Os dados apresentados em trabalhos anteriores possibilitam aﬁrmar que esses
anticorpos associados ao padrão RR estão fortemente relacionados com o tratamento da
hepatite C. Além disso, pode-se aﬁrmar que a ocorrência de reatividade anti-RR é promovida
pela  terapia combinada com interferon alfa e ribavirina.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
eters; and a hematocrit of 23%, associated with normal valuesIntroduction
Hepatitis C virus (HCV) is an RNA virus of the Flaviviri-
dae family, genus Hepacivirus, with a high rate of hepatic
replication. This is an enveloped virus, with a size between
30 and 40 nm.1–3 HCV was originally isolated in a serum
sample of an individual with non-A, non-B hepatitis in
1989 by Choo et al.4 Since then, hepatitis C gained special
relevance among the causes of chronic liver disease world-
wide. In 1992, the ﬁrst test for identiﬁcation of the antibody
against HCV was developed, providing greater safety in blood
transfusions.1,2
The HCV transmission occurs through contact with
infected blood due to percutaneous exposure, blood and/or
blood products transfusion and transplants from infected
donors. Although some patients with acute HCV infection
have an immune system able of eliminating the virus,
55–58% of patients develop chronic infection, deﬁned as
the persistence of infection for no less than six months,
with only 10–15% of cases reaching spontaneous healing.
The hepatocellular injury, seen in chronic HCV infection,
does not seem to be directly related to a viral cytopathic
effect, being related to immune mediators, with natural killer
cells and CD8 + T lymphocytes playing a central role in the
pathogenesis.1,2
The treatment of HCV infection aims to control the
progression of liver disease by inhibiting viral replication. Fur-
thermore, the reduction in inﬂammatory activity prevents its
progression to cirrhosis and hepatic carcinoma. The recom-
mended therapy for chronic HCV infection is a combination
of a formulation of interferon alpha and ribavirin.3Interferon is a cytokine which composes the innate
response of the human host. The addition of one polyethyl-
ene glycol molecule to the interferon molecule prolongs the
action, increases the rate of absorption, extends the half-life
and reduces the clearance of interferon. Ribavirin is a nucleo-
side analog antiviral agent used orally, with a wide spectrum
of action against viral pathogens. Ribavirin also has the effect
of modulating the immune response.2,3 Mori et al. recently
demonstrated that ribavirin in therapeutic doses inhibits the
replication of HCV RNA, and proposed that this anti-HCV
activity is mediated through the inhibition of inosine-5′-
monophosphate dehydrogenase (IMPDH).5
Case  report
Female patient complaining of asthenia and pain at hypogas-
tric area, admitted on October 4, 2011 in the emergency room
of Hospital Universitário do Oeste do Paraná (HUOP) in the city
of Cascavel-PR. During anamnesis, the patient reported treat-
ment of chronic infection with hepatitis C virus with pegylated
interferon alpha and ribavirin, starting on December 7, 2010
and concluded on November 1, 2011. During this period the
patient developed severe pancytopenia due to the adverse
effects of the medication.
On admission, routine laboratory tests were performed and
the results showed signiﬁcant changes in blood count param-of MCH  (mean corpuscular hemoglobin), together with clinical
data obtained at the time of anamnesis, raised the diagnostic
hypothesis of autoimmune anemia. In an attempt to conﬁrm
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Fig. 1 – Rods measuring 3–10 m and rings with 2–5 m of
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riameter, scattered across the cell cytoplasm.
he diagnosis of autoimmune disease, a search for autoan-
ibodies against cellular antigens (PAAC-HEp-2), traditionally
nown as antinuclear antibodies (ANA), was requested, show-
ng ﬂuorescence in the shape of rods and/or rings in the cell
ytoplasm.
This description of a clinical case aims to bring current
nformation about this ﬂuorescence pattern found in Hep-2
ells, not yet completely understood, in an attempt to under-
tand its relationship with the clinical picture of the patient.
iscussion
ecently, a new cytoplasmic pattern in PAAC-HEp-2 has been
eported in patients with HCV. This pattern is characterized
y rods with 3–10 m and rings with 2–5 m in diameter, scat-
ered across the cell cytoplasm (Fig. 1). Because of that, this
attern has been designated as “rods and rings” (RR).6
Seelig et al., when doing a search for PAAC-HEp-2, detected
he RR pattern in a serum sample of a patient, and the anti-
enic target of this reaction was identiﬁed through searches in
atabases as being IMPDH type 2, which is a key enzyme in the
ynthesis of puric nucleotides.7 In the study by Carcamo et al.,
ell cultures treated with ribavirin showed that this drug has
he ability to induce the formation of the RR pattern; on the
ther hand, in in vivo tests 25% of HCV positive patients treated
ith ribavirin and interferon alpha had anti-RR antibodies,
hile none of the untreated subjects developed this pattern.8
In mammals, there are two isoforms of this enzyme,
MPDH1 and IMPDH2. While IMPDH1 is constitutively
xpressed in normal cells, the expression and activity of
MPDH2 are increased in malignant cells.8 Therefore, HEp-2
ells, by being originated from human laryngeal carcinoma,
resent increased expression and activity of IMDH2 enzyme.
IMPDH2, aggregated or modiﬁed in the form of RR in
hese patients treated with inhibitors of this enzyme such
s ribavirin, may become antigenic and induce an autoim-
une response. It is possible that interferon alpha stimulates
he occurrence of anti-RR reactivity apparently induced by
ibavirin.6–8
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Keppeke et al. carried out a longitudinal study and analyzed
samples from 597 patients using indirect immunoﬂuores-
cence (IIF) technique in HEp-2 slides. The RR pattern was
observed in 14.1% of 342 patients with HCV,  and none of
the 117 patients without HCV showed this pattern. Regarding
treatment, anti-RR antibodies were present in 38% of 108
patients receiving interferon alpha and ribavirin, but nei-
ther of the 26 patients receiving monotherapy with interferon
alpha or ribavirin nor those 166 untreated patients presented
RR.
In this study we observed the presence of antibodies anti-
RR just after the beginning of treatment, with its appearance
starting within the ﬁrst month in 6% of patients; however, at
six months more  than 47% of the tested samples presented the
RR pattern. Another relevant fact of this study was that, among
anti-RR-positive patients, 77% did not respond to treatment.
On the other hand, among anti-RR-negative patients, the rate
was 64%. Thus, this pattern is not related to the success of
drug therapy.8
When it comes to RR pattern, there is discrepancy in the
results obtained in PAAC-HEp-2 with IIF by using slides from
different manufacturers, and this remains a not completely
resolved issue, but that may stem from differences in culture
conditions, sample processing, or both.7,8 This difﬁculty was
also found in our laboratory, considering that, when faced with
this pattern, hitherto unknown, it was necessary to conﬁrm it
with slides of various trademarks; but we observed the forma-
tion of RR pattern only in one of the commercial slides used,
thus creating doubts about the relevance of the pattern. In fact,
in most of the HEp-2-positive slides, serum samples positive
for the RR pattern produce a non-speciﬁc spotted cytoplasmic
pattern, or present no signiﬁcant reaction.6
The identiﬁcation of a new autoantibody associated with
a given pathology may contribute to the understanding of its
pathophysiology and can enrich the arsenal of diagnostic tests
for this disease.6 It is therefore important that further studies
are conducted, in order to understand the clinical signiﬁcance
of this cytoplasmic pattern.
Data presented in this study revealed that antibodies asso-
ciated to RR pattern are strongly associated with the treatment
of hepatitis C; that the occurrence of anti-RR reactivity is
promoted by a combined therapy with interferon alpha and
ribavirin; and that its frequency increases with the duration
of treatment. However, the same was not observed when
these drugs are used separately. Furthermore, previous studies
showed no relationship between this pattern and demo-
graphic parameters, duration of diagnosis of HCV, treatment
response pattern, HCV genotype or viral load.8
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